MDPV
1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one
Overview
MDPV belongs to Stimulants / Cathinones.
Effects
- Intense stimulation, euphoria, alertness, increased energy, sociability and drive: broadly cocaine- or amphetamine-like but longer-lasting.
- Strong sympathetic effects: raised heart rate and blood pressure, dilated pupils, reduced appetite, jaw clenching, and often anxiety, restlessness and insomnia.
- At higher doses or when bingeing: compulsive redosing, paranoia, panic, agitation, hallucinations and stimulant psychosis, followed by a heavy 'comedown' of exhaustion, low mood and craving.
Dosing & duration
Oral or insufflated (also used intravenously and rectally). The values below are approximate oral figures. MDPV is extremely potent, active from just a few milligrams, so the ranges are narrow and small errors matter. An accurate milligram scale is essential and eyeballing is dangerous. The effects and cravings drive compulsive redosing that easily leads to multi-day binges with sleeplessness, hyperthermia and psychosis, so redosing should be avoided. Never combine with other stimulants or MAOIs. 'Bath salts'/'monkey dust' products are of unknown identity and strength, so test the substance.
Dose ranges
2 mg
4–8 mg
8–14 mg
14–25 mg
25 mg +
Duration
15–30 min
2–7 h (craving and stimulation persist longer)
2–48 h (insomnia, anxiety, craving, low mood)
Chemical & Physical Properties
| Formula | C16H21NO3 |
| Molar mass | 275.34 g/mol |
| State | Solid (usually the hydrochloride salt, crystalline, free base is an oil) |
| Melting point | 238–239 °C (with decomposition, hydrochloride salt) |
| Boiling point | Not reported |
| Density | Not reported |
| Vapor pressure | Not reported |
| pKa | Not reported |
| LogP | 3.3 (predicted, XLogP3, free base) |
| Solubility | Hydrochloride salt: soluble in water, methanol and chloroform (the white-powder form the drug is normally encountered as) |
| Refractive index | Not reported |
Identifiers & Synonyms
| CAS | 687603-66-3 |
| CAS (enantiomer) | |
| PubChem CID | 20111961 |
| InChIKey | SYHGEUNFJIGTRX-UHFFFAOYSA-N |
| InChI | InChI=1S/C16H21NO3/c1-2-5-13(17-8-3-4-9-17)16(18)12-6-7-14-15(10-12)20-11-19-14/h6-7,10,13H,2-5,8-9,11H2,1H3 |
| SMILES | CCCC(C(=O)C1=CC2=C(C=C1)OCO2)N1CCCC1 |
Synonyms
- Methylenedioxypyrovalerone
- MDPV
- Bath salts (component)
- Monkey dust
Pharmacodynamics & Biochemistry
MDPV (3,4-methylenedioxypyrovalerone) is a synthetic cathinone of the pyrrolidinophenone ('pyrovalerone') family. Unlike most cathinones and unlike the amphetamines, it does not release monoamines. It is a potent, selective noradrenaline–dopamine reuptake inhibitor (NDRI): it blocks the dopamine (DAT) and noradrenaline (NET) transporters so that released dopamine and noradrenaline accumulate in the synapse. It is exceptionally potent at DAT, on the order of ten times more potent than cocaine, with almost no serotonergic activity, a profile that gives it strong cocaine/amphetamine-like reinforcing and psychostimulant effects and a high addiction and psychosis potential. In transfected human cells its uptake-inhibition potency is about IC50 31 nM at DAT and 44 nM at NET, versus roughly 9,300 nM at the serotonin transporter (a DAT/SERT selectivity ratio over 100). S-(+)-MDPV is the active enantiomer. R-(−)-MDPV is far less potent, and the drug is used as the racemate.
Biological targets
- DAT
- NET
Binding & functional measurements
| Target | Measurement | Species |
|---|---|---|
| Dopamine transporter | Ki 10 ± 2.0 nM | Human |
| Noradrenaline transporter | Ki 80 ± 20 nM | Human |
| Serotonin transporter | Ki 2,860 ± 100 nM | Human |
| TAAR1 | Ki 7,200 ± 1,100 nM | Rat |
Pharmacokinetics
| Bioavailability | Insufflated/oral, rapid |
| Tmax | Not reported |
| Half-life | Short, effects prolonged by redosing |
| Vd | Not reported |
| Protein binding | Not reported |
| Metabolism | Hepatic CYP2D6 demethylenation |
| Excretion | Renal |
Toxicology & Safety
Not reported
MDPV is one of the more dangerous stimulants sold on the street. Its potent, purely catecholaminergic (dopamine/noradrenaline) action, long duration and tendency to cause compulsive redosing make it strongly addictive and prone to multi-day binges with severe sleep deprivation. It is notorious for acute psychiatric and physical crises: intense agitation, paranoia, panic and stimulant psychosis with hallucinations, and an 'excited/agitated delirium' picture with dangerous hyperthermia, tachycardia, hypertension, muscle breakdown (rhabdomyolysis) and kidney failure that has caused deaths. Because it is so potent, only a few milligrams separate an active from a heavy dose, so eyeballing is very risky. It should never be combined with other stimulants (additive cardiovascular and hyperthermic toxicity) or with MAOIs, and products sold as 'bath salts' or 'monkey dust' are of unknown content and strength.[3][5]
Legal Status
US: Schedule I. UK: Class B. DE: BtMG Anlage II
Interactions & Contraindications
Drug interactions
Contraindications
No interactions or contraindications listed.
Usage & Context
- A recreational stimulant, widely sold from around 2010 as a component of 'bath salts' (and later 'monkey dust'), used for cocaine/amphetamine-like euphoria, stimulation and disinhibition: often insufflated, swallowed or, more dangerously, injected.
- Originally synthesised in the 1960s (Boehringer Ingelheim) but never developed as a medicine. It re-emerged as a 'legal high'/research-chemical stimulant before being banned in most countries.
- It has no medical use and is now a controlled substance (US Schedule I, UK Class B, DE Anlage II BtMG).
Sources & Evidence
- PubChem: MDPV (CID 20111961) — identifiers & computed properties
- Simmler LD, Buser TA, Donzelli M, et al. (2013). Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458-70.
PMID 22897747 · doi:10.1111/j.1476-5381.2012.02145.x
- Wikipedia: MDPV — pharmacology (NDRI, DAT/NET potency, enantiomers), effects, harms & legal status CC BY-SA 4.0
- PsychonautWiki: MDPV — recreational dosage, duration & subjective effects CC BY-SA 4.0
- EMCDDA (EUDA): Synthetic cathinones drug profile — MDPV effects, harms & control
- DEA Diversion Control Division: Controlled Substance Schedules (MDPV is Schedule I)
- GOV.UK: Controlled drugs list — MDPV is Class B (Misuse of Drugs Act 1971) OGL v3.0
- Anlage II BtMG — Betäubungsmittelgesetz (Gesetze im Internet): MDPV ist verkehrsfähig, aber nicht verschreibungsfähig (seit 2012)